In short
A groundbreaking Phase 3 clinical trial is underway to assess the efficacy and safety of AOC 1001, a promising new drug for treating Myotonic Dystrophy Type 1 (DM1). This study aims to evaluate how AOC 1001, administered intravenously, affects hand function, mobility, muscle strength, and overall quality of life in patients with DM1. The trial represents a significant step forward in developing targeted therapies for this rare genetic disorder.
At a glance
- Study Type
- Phase 3, Randomized, Double-Blind, Placebo-Controlled, Global Study
- Drug Name
- AOC 1001
- Target Condition
- Myotonic Dystrophy Type 1 (DM1)
- Primary Endpoint
- Change in video Hand Opening Time (vHOT) from baseline to Week 30
- Key Secondary Endpoints
- Changes in hand grip strength, muscle strength (QMT scores), mobility (10MWRT), and quality of life measures (DM1-ActivC, EQ-5D-5L)
- Dosing
- Intravenous infusion, max 4 mg/kg daily, 28 mg/kg total over 54 weeks
- Key Inclusion Criteria
- Age 16-65, DM1 diagnosis with CTG repeat ≥100, ability to walk 10 meters independently
- Key Exclusion Criteria
- Pregnancy, uncontrolled diabetes, recent heart failure, BMI >35 kg/m²
What is AOC 1001?
AOC 1001 is an innovative medication being developed to treat Myotonic Dystrophy Type 1 (DM1). It is classified as a humanised IgG1 monoclonal antibody that targets a specific protein called TFR1. This antibody is connected to a special type of genetic material (siRNA) that targets a gene called DMPK, which is involved in DM1.
In simpler terms, AOC 1001 is designed to deliver a targeted treatment directly to the cells affected by DM1. It combines two important components:
- An antibody that helps the drug reach the right cells
- A genetic component that aims to reduce the harmful effects of the faulty gene in DM1
Target Condition: Myotonic Dystrophy Type 1
Myotonic Dystrophy Type 1 (DM1) is a genetic disorder that affects muscles and many other body systems. It causes muscle weakness, difficulty relaxing muscles (myotonia), and can impact the heart, brain, and other organs. DM1 is caused by a specific genetic change in the DMPK gene.
Clinical Trial Overview
A Phase 3 clinical trial is currently underway to evaluate the effectiveness and safety of AOC 1001 for treating DM1. This study is:
- Randomized: Participants are randomly assigned to either receive AOC 1001 or a placebo
- Double-blind: Neither the participants nor the researchers know who is receiving the actual drug
- Placebo-controlled: Some participants will receive a placebo (an inactive substance) for comparison
- Global: The study is being conducted in multiple countries
This trial represents an advanced stage of research, aiming to confirm the drug's benefits and safety in a larger group of patients.
Eligibility Criteria
To participate in this study, individuals must meet certain criteria. Some key inclusion criteria are:
- Age: 16 to 65 years old (18-65 in Denmark and Germany)
- Confirmed diagnosis of DM1, both clinically and genetically (with at least 100 CTG repeats in the affected gene)
- Ability to walk independently for at least 10 meters (use of ankle braces or orthoses is allowed)
Some exclusion criteria include:
- Pregnancy or breastfeeding
- Uncontrolled diabetes
- Recent history of heart failure
- Body Mass Index (BMI) greater than 35 kg/m²
- Recent use of certain medications or participation in other clinical trials
These criteria help ensure the safety of participants and the reliability of the study results.
Study Objectives and Endpoints
The main goal of this study is to evaluate how well AOC 1001 improves hand function in people with DM1. Researchers will measure this by looking at the change in video Hand Opening Time (vHOT) from the start of the study to week 30.
Other important aspects being studied include:
- Changes in muscle strength and function
- Improvements in mobility
- Patient-reported outcomes (how patients feel the treatment is affecting their daily lives)
These will be measured using various tests and questionnaires, such as:
- Hand grip strength: Measures how strongly a person can grip
- QMT (Quantitative Muscle Testing): Assesses strength in different muscle groups
- DM1-ActivC: A questionnaire about daily activities specific to DM1 patients
- 10MWRT (10-Meter Walk/Run Test): Measures walking speed
- PGI-S and PGI-C: Patient-reported impressions of symptom severity and change
- EQ-5D-5L: A general health-related quality of life questionnaire
These measurements will be taken at various points during the study, including at 30 weeks and 54 weeks after starting treatment.
Drug Administration
AOC 1001 is given as an intravenous infusion, which means it's delivered directly into the bloodstream through a vein. The maximum daily dose is 4 mg/kg (milligrams per kilogram of body weight), with a total maximum dose of 28 mg/kg over the course of treatment. The treatment period lasts up to 54 weeks.
Potential Benefits and Orphan Drug Status
While the full benefits of AOC 1001 are still being studied, its development as a targeted therapy for DM1 offers hope for patients with this rare disease. The European Union has granted AOC 1001 orphan drug designation (EU/3/21/2485), which is given to medicines intended for the treatment of rare diseases. This status can help accelerate the development and approval process for drugs that address significant unmet medical needs.
It's important to note that as this is an ongoing clinical trial, the effectiveness and safety of AOC 1001 are still being evaluated. Patients interested in this treatment should discuss it with their healthcare providers and consider the potential risks and benefits of participating in clinical research.